Coherus Oncology (CHRS) Other Working Capital Changes (2013 - 2026)

Coherus Oncology has disclosed Other Working Capital Changes across 14 years of filings, most recently posting -$15.1 million for Q2 2026.

• In Q2 2026, Other Working Capital Changes rose 346.23% year-over-year to $38.9 million; the TTM figure through Jun 2026 stood at -$32.8 million (down 587.87% YoY), while the FY2025 annual figure was -$64.4 million, changed N/A from the prior year.
• Other Working Capital Changes came in at -$15.1 million for Q2 2026 at Coherus Oncology, down from $3.1 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $38.9 million in Q2 2026 to a low of -$51.8 million in Q4 2025.
• Average Other Working Capital Changes over 3 years is -$2.7 million, with a median of $1.8 million recorded in 2025.
• Year-over-year, Other Working Capital Changes sank 223.09% in 2025 and surged 346.23% in 2026.
• Over 5 years, Other Working Capital Changes stood at $915000.0 in 2022, then sank by 695.96% to -$5.5 million in 2023, then jumped by 36.4% to -$3.5 million in 2024, then tumbled by 43.48% to -$5.0 million in 2025, then plunged by 203.48% to -$15.1 million in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were -$15.1 million in Q2 2026, $3.1 million in Q1 2026, and -$5.0 million in Q4 2025.